Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One Inks Deal With NeoGenomics to Interpret Cancer Dx Tests

NEW YORK (GenomeWeb) – Bioinformatics firm N-of-One today announced an agreement with NeoGenomics to interpret the results of tests performed by the cancer genetics diagnostics firm.

Under the agreement, Lexington, Mass.-based N-of-One will provide clinical and interpretive evidence for NeoGenomics' NeoType solid tumor NGS tests, which report the most common and actionable genomic abnormalities in various subtypes of solid tumors.

Financial terms of the agreement were not disclosed.

"NeoGenomics selected N-of-One because of their oncology domain expertise and the flexible and efficient approach to tailoring their interpretation to meet our needs," NeoGenomics Chief Medical Officer Maher Albitar of said in a statement.

Fort Meyers, Fla.-based NeoGenomics is a high-complexity CLIA-certified clinical laboratory that provides a series of cancer testing services, including cytogenetics, FISH, flow cytometry, immunohistochemistry, and molecular genetic testing.

N-of-One provides highly scalable, cost-effective, patient-specific clinical interpretation for oncology testing.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.